Abstract
Lymphocytes infiltrating tumor tissue are capable of androstenedione conversion, which was assessed from3H2O release from tritium-labeled androgen precursor of estrogens 1β-androstenedione. This capacity is higher in menopausal patients than in patients of reproductive age. A tendency to a positive correlation between the intensity of androstenedione conversion in lymphocytes and aromatase activity in tumor tissue is revealed. No relationship between androstenedione conversion in lymphocytes and contamination of the isolated cell suspension with tumor cells is detected.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
